Mobilization and transplantation of Philadelphia-negative peripheral- blood progenitor cells early in chronic myelogenous leukemia

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1575-1582

  Carella, A M ^a   Cunningham, I ^a   Lerma, E ^a   Dejana, A ^a   Benvenuto, F ^a   Podesta M ^a   Celesti, L ^a   Chimirri, F ^a   Abote, M ^a   Vassallo, F ^a   Figari, O ^a   Parodi, C ^a   Sessarego, M ^a   Valbonesi, M ^a   Carlier, P ^a   Prencipe, E ^a   Gatti, A M ^a   van den Berg, D ^a   Hoffman, R ^a   Frassoni, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIEMETIC AGENT; BUSULFAN; CYTARABINE; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOGENETICS; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL;

EID: 0030901019     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1575     Document Type: Article

References (38)

1. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825, 1994
2. Allan NC, Richards SM, Shepherd PCA: UK Medical Research Council randomised, multicentre trial of interferon-α for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392-1397, 1995
3. Talpaz M, Kantarjian H, Kurzrock R, et al: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 114:532-538, 1991
4. Helmann R, Helmpel H, Hasford J, et al: Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 134:4064-4077, 1994
5. Buckner CD, Stewart P, Clift RA, et al: Treatment of blastic transformation of chonic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 6:96-99, 1978
6. Marcus RE, Goldman JM: Autografting in chronic granulocytic leukemia. Clin Haematol 15:235-239, 1986
7. McGlave PH, DeFabritiis P, Deisseroth A, et al: Autologous transplants for chronic myelogenous leukemia: Results from eight transplant groups. Lancet 343:1486-1491, 1994
8. Carella AM, Gaozza E, Raffo MR, et al: Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 5:517-521, 1991
9. - cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia. J Hematother 3:199-204, 1994
10. Deisseroth AB, Zu Z, Claxton D, et al: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in chronic myelogenous leukemia. Blood 83:3068-3076, 1994
11. Murray L, Chen B, Galy A, et al: Enrichment of human hematopoiesis stem cell activity in the CD34+ Thyl+ Lin- subpopulation from mobilized peripheral blood. Blood 85:368-374, 1995
12. Ackerstein A, Kedar E, Slavin S: Use of recombinant interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disorders. Blood 78:1212-1218, 1991
13. Foa R, Fierro MT, Tosti S, et al: Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leukemia Lymphoma 1:113-119, 1990
14. Slavin S, Ackerstein A, Weiss L: Adoptive immunotherapy in conjunction with bone marrow transplantation-amplification of natural best defence mechanisms against cancer by recombinant IL-2. Nat Immun Cell Growth Reg 7:180-187, 1988
15. Podestà M, Piaggio G, Frassoni F, et al: Very primitive hemopoietic cells (LTC-IC) are present in Philadelphia negative cytaphereses collected during early recovery after chemotherapy for chronic myelogenous leukemia. Bone Marrow Transplant 16:549-555, 1995
16. Goldman JM, Th'ng KH, Lowenthal RM: In vitro colony forming cells and colony stimulating factor in chronic granulocytic leukaemia. Br J Cancer 30:1-12, 1974
17. Frassoni F, Piaggio G, Podestà M, et al: Spontaneous exodus of high numbers of normal stem cells (Ph-negative LTC-ICs) in patients with chronic myeloid leukemia at the beginning of the disease. Blood 86:10, 1995 (abstr 3164; suppl)
18. Petzer AL, Lansdorp PM, Shaw GJ, et al: Elevated numbers of CD38-, Thyl+LTC-IC are present in the blood of newly diagnosed CML patients and include both Ph- and Ph+ genotypes. Exp Hematol 23:791-796, 1995 (suppl 8)
19. Korbling M, Burke P, Braine H, et al: Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol 9:684-687, 1981
20. Carella AM, Podestà M, Frassoni F, et al: Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 12:267-271, 1993
21. Kantarjian HM, Talpaz M, Hester J, et al: Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive dose chemotherapy. J Clin Oncol 13:553-559, 1995
22. Talpaz M, Kantarjian H, Liang J, et al: Percentage of Philadelphia-chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for CML depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 85:3257-3263, 1995
23. Hoyle C, Gray R, Goldman J: Autografting for patients with CML in chronic phase: An update. Br J Haematol 86:76-81, 1994
24. Meloni G, Vignetti M, Cardillo AMF, et al: Ablative chemotherapy followed by peripheral blood stem cells reinfusion for chronic myelogenous leukemia in chronic phase. Bone Marrow Transplant 14:103, 1994 (suppl 3; abstr)
25. Reiffers J, Goldman J, Meloni G: Autologous stem cell transplantation in chronic myelogenous leukemia: A retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 14:51-54, 1994 (suppl 3)
26. Simonsson B, Oberg G, Killander A, et al: Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia (CML). Bone Marrow Transplant 14:555-556, 1994 (suppl 3)
27. Mc Glave P, Miller J, Perry E, et al: Autologous marrow transplant therapy for chronic myelogenous leukemia using marrow treated ex vivo with human recombinant interferon gamma. Blood 84:537a, 1994 (suppl 1; abstr)
28. Vogler WR, Winton EF, James S, et al: Autologous marrow transplantation after karyotipic conversion to normal in blastic phase of chronic myelocytic leukemia. Am J Med 75:1080-1086, 1983
29. Carlo-Stella C, Mangoni L, Almici C, et al: Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 14:425-432, 1994
30. Barnett MJ, Eaves CJ, Phillips GL, et al: Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study. Blood 84:724-732, 1994
31. Brunda MJ, Tarnowsld D, Davatelis V: Interaction of recombinant interferons with recombinant interleukin-2. Differential effects on natural killer cell activity and interleukin-2 activated killer cells. Int J Cancer 37:787-791, 1986
32. Brunda MJ, Bellantoni D, Sutich V: In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40:365-370, 1987
33. Igio M, Sakurai M, Tamura T, et al: In vivo anti-tumor activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 48:260-264, 1988
34. Kuribayashi K, Gillis S, Kern DE, et al: Murine NK cell cultures: Effects of interleukin-2 and interferon on cell growth and cytotoxic activity. J Immunol 126:2321-2325, 1981
35. Verfaillie C, Kay N, Miller W, et al: Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 76:401-406, 1990
36. Hauch M, Gazzola MV, Small T, et al: Anti-leukemia potential of interleukin-2 activated natural killer cells after hone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250-2257, 1990
37. Dabholkar M, Tatake R, Amin K, et al: Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission. Oncology 46:123-128, 1989
38. Nagler A, Ackerstein A, Barak V, et al: Treatment of chronic myelogenous leukemia with rhIL-2 and interferon-α-2a. J Hematother 11:31-39, 1994